Asset medical lifecycle plan
The challenge
US and EU regulatory agencies provided the client with new guidance on generating supportive evidence for the proposed launch indication and future indications for a breakthrough vaccine. The client team wished to understand the potential impact of this information on the lifecycle and to develop an updated indication strategy.
Our solution
We identified key criteria for populations of interest and the relevant decision-making criteria to aid prioritization. We also assessed potential indications, including their evidence and regulatory needs, and facilitated a team workshop to align on prioritization of data generation initiatives and indications.
The results
Ultimately, we leveraged guidance received from regulatory authorities and input from the cross-functional team to develop an indication expansion strategy for long-term success.
Jump to a slide with the slide dots.
Patient Finding Through Data Tokenization
Refined HCP targeting in rare disease using integrated data, boosting hit rates from 10% to 50% and delivering 3x ROI in 6 months.
Read moreDigital share of voice and sentiment analysis at key congress
Used GenAI to benchmark digital voice in oncology, boosting engagement & leadership via LinkedIn, DEI & clinical messaging.
Read moreData Strategy Development
Future-proofed data strategy with Putnam: gaps identified, vendors vetted, leading to a first US multi-source tokenized DB.
Read more